This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

PharMerica Reports First Quarter 2014 Results

Stocks in this article: PMC

PharMerica Corporation (NYSE:PMC), a national provider of institutional, specialty home infusion, hospital and oncology pharmacy services, today reported its financial results for the first quarter ended March 31, 2014.

First Quarter 2014 Highlights (Comparisons to First Quarter 2013)

  • Revenues of $452.2 million, an increase of 3%
  • Adjusted EBITDA of $29.7 million, a decrease of 14%
  • Adjusted diluted earnings per share of $0.37, a decrease of 20%
  • Net organic sales growth in the institutional pharmacy business continues, excluding previously disclosed bed losses
  • Strategic investment in Onco360 driving revenue growth
  • Generic drug dispensing rate increased to industry-leading 84.5%

Greg Weishar, PharMerica Corporation’s Chief Executive Officer, said, “We are positioning PharMerica to drive long-term growth and value creation, and we are encouraged that first quarter results demonstrate solid progress toward those objectives. During the quarter we achieved year-over-year and sequential revenue growth that exceeded expectations. Revenue growth was primarily driven by specialty operations. Consequently, we achieved another quarter of sequential sales growth while at the same time improving our industry-leading generic dispensing rate.”

Mr. Weishar added, “Under the previously announced strategic purchasing initiative, we are advantageously deploying cash flow from operating activities to enhance gross margins. Through the balance of 2014, we will prudently invest in inventory levels that maximize buy side margin. At the same time, we continue to focus on both organic and external growth opportunities. With a solid quarter behind us, we are confident that 2014 will be a successful year of transition and that PharMerica is poised to deliver improving financial results in 2015 and beyond.”

Full Year 2014 Financial Guidance

PharMerica today updated its full year 2014 guidance metrics. For the full year 2014, the Company now expects:

  • Revenue in the range of $1.70 billion to $1.75 billion from $1.67 billion to $1.72 billion
  • Adjusted diluted earnings per share in the range of $1.40 to $1.50 from $1.35 to $1.50
  • Adjusted EBITDA in the range of $117.5 million to $123.0 million from $115.0 million to $123.0 million

The Company notes that its 2014 guidance does not include the effect of any potential 2014 acquisitions. PharMerica is targeting acquisitions that generate at least $100 million of annualized sales, in the aggregate, in each of 2014 and 2015.

1 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,356.87 +288.00 1.69%
S&P 500 2,012.89 +40.15 2.04%
NASDAQ 4,644.3120 +96.4780 2.12%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs